Table 1.
Characteristics of medulloblastoma patients with non-WNT/non-SHH tumors
| ID | Group | Gender | Age years | Metastases | Histopathology | Patient status | PFS mts | OS mts | iso17 or 17q gain | PHOS IHC |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | INT 3/4 | m | 5 | M0M1 | Classic | ADF | 69 | 69 | + | + |
| 2 | INT 3/4 | f | 8 | M2,3 | Classic | ADF | 88 | 88 | nd | − |
| 3 | INT 3/4 | f | 7 | M0M1 | Classic | ADF | 67 | 67 | + | + |
| 4 | INT 3/4 | m | 5 | M2,3 | Classic | ADF | 48 | 48 | − | + |
| 5 | INT 3/4 | f | 8 | M2,3 | Classic | ADF | 45 | 45 | + | + |
| 6 | INT 3/4 | f | 7 | M2,3 | LCA | ADF | 89 | 89 | nd | + |
| 7 | INT 3/4 | f | 15 | M0M1 | LCA | ADF | 67 | 67 | nd | + |
| 8 | INT 3/4 | m | 6 | M0M1 | Classic | ADF | 48 | 48 | + | + |
| 9 | INT 3/4 | m | 12 | M0M1 | Classic | ADF | 111 | 111 | nd | + |
| 10 | INT 3/4 | m | 13 | M0M1 | Classic | ADF | 55 | 55 | + | − |
| 11 | INT 3/4 | m | 5 | M0M1 | MBL | ADF | 72 | 72 | nd | nd |
| 12 | 3 | m | 3 | M2,3 | LCA | DOD | 14 | 15 | + | + |
| 13 | 3 | f | 6 | M2,3 | LCA | DOD | 12 | 29 | + | + |
| 14 | 3 | f | 17 | M0M1 | Classic | DOD | 24 | 26 | nd | nd |
| 15 | 3 | m | 13 | M0M1 | LCA | DOD | 25 | 26 | + | + |
| 16 | 3 | m | 8 | M2,3 | Classic | DOD | 24 | 44 | nd | + |
| 17 | 3 | m | 1.5 | M2,3 | LCA | DOD | 26 | 29 | + | + |
| 18 | 3 | m | 11 | M0M1 | LCA | ADF | 122 | 122 | nd | + |
| 19 | 3 | m | 5 | M0M1 | Classic | ADF | 126 | 126 | + | + |
| 20 | 3 | m | 3 | M2,3 | Classic | ADF | 68 | 68 | + | + |
| 21 | 4 | m | 10 | M2,3 | Classic | DOD | 12 | 24 | + | − |
| 22 | 4 | m | 15 | M2,3 | NOS | DOD | 60 | 97 | nd | − |
| 23 | 4 | m | 12 | M2,3 | Classic | DOD | 37 | 42 | + | − |
| 24 | 4 | f | 13 | M0M1 | LCA | Secondary leukaemia | 36 | 36 | nd | − |
| 25 | 4 | m | 14 | M0M1 | Classic | DOD | 26 | 32 | nd | − |
| 26 | 4 | m | 17 | M2,3 | LCA | DOD | 22 | 23 | − | − |
| 27 | 4 | m | 10 | M0M1 | Classic | DOD | 35 | 46 | + | − |
| 28 | 4 | m | 14 | M2,3 | Classic | ADF | 83 | 83 | + | − |
| 29 | 4 | m | 8 | M2,3 | Classic | ADF | 73 | 73 | + | − |
| 30 | 4 | m | 9 | M0M1 | Classic | ADF | 57 | 57 | + | − |
| 31 | 4 | m | 11 | M0M1 | Classic | ADF | 85 | 85 | + | − |
| 32 | 4 | m | 5 | M2,3 | Classic | ADF | 191 | 191 | nd | − |
| 33 | 4 | m | 14 | M2,3 | LCA | ADF | 57 | 57 | + | − |
| 34 | 4 | m | 8 | M2,3 | Classic | ADF | 142 | 142 | nd | − |
| 35 | 4 | m | 10 | M0M1 | Classic | ADF | 113 | 113 | + | − |
| 36 | 4 | m | 9 | M0M1 | Classic | ADF | 61 | 61 | − | − |
| 37 | 4 | f | 12 | M0M1 | Classic | ADF | 119 | 119 | + | − |
| 38 | 4 | m | 14 | M0M1 | Classic | ADF | 51 | 51 | + | − |
| 39 | 4 | m | 5 | M0M1 | Classic | ADF | 48 | 48 | nd | − |
| 40 | 4 | m | 7 | M0M1 | Classic | Secondary GBM | 101 | 101 | nd | − |
| 41 | 4 | f | 15 | M0M1 | Classic | ADF | 61 | 61 | nd | − |
| 42 | 4 | m | 10 | M0M1 | NOS | ADF | 73 | 73 | nd | − |
| 43 | 4 | f | 4 | na | LCA | na | na | na | nd | − |
| 1341 | MAGIC 4 | m | 7 | M0M1 | Classic | ADF | 102 | 102 | + | + |
| 1345 | MAGIC 4 | f | 12 | M0M1 | Classic | ADF | 97 | 97 | + | + |
| 847 | MAGIC 4 | m | 12 | M3 | LCA | ADF | 97 | 97 | − | + |
| 1121 | MAGIC 4 | m | 4 | M0M1 | Classic | ADF | 91 | 91 | − | + |
| 132 | MAGIC 4 | f | 7 | M0M1 | Classic | ADF | 159 | 159 | nd | + |
MAGIC 4 Group 4 according to the Medulloblastoma Advanced Genomics International Consortium study, LCA large cell/anaplastic, NOS not otherwise specified, ADF alive disease free, GBM glioblastoma, PHOS phosducin, IHC immunohistochemistry, na not available, nd not done, m male, f female, mts months